Randall Michael Giuffre, Director at DiaMedica Therapeutics Inc. (DMAC), bought 11,250 shares at $4.00 ($45K) on 2018-12-11, disclosed to the SEC on 2018-12-11.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| DMAC | BUY | 2022-12-08 | $35K | — | Filing → |
| DMAC | BUY | 2022-12-05 | $975 | — | Filing → |
| DMAC | BUY | 2022-12-01 | $136K | — | Filing → |